ReviewJournal of endocrinological investigation2015
Cardiovascular risk factors and events in women with androgen excess.
Review in Journal of endocrinological investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Gender-Specific Associations Between Sex Hormones and Cardiovascular Disease: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2026Pooled it
- Association of PON1 gene polymorphisms with polycystic ovarian syndrome risk: a meta-analysis of case-control studies.Journal of endocrinological investigation · 2018Pooled it
- Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms.BioMed research international · 2026Review
- Estradiol and dihydrotestosterone exert sex-specific effects on human fibroblast and endothelial proliferation, bioenergetics, and vasculogenesis.Communications biology · 2025Article
- PCOS - the many faces of a disorder in women and men.Journal of endocrinological investigation · 2025Review
- Metabolic Syndrome Spectrum in Children with Classic Congenital Adrenal Hyperplasia-A Comprehensive Review.Metabolites · 2025Review
- Alterations of cardiometabolic risk profile in polycystic ovary syndrome: 13 years follow-up in an unselected population.Journal of endocrinological investigation · 2024Article
- Insights on the NF-κB system in polycystic ovary syndrome, attractive therapeutic targets.Molecular and cellular biochemistry · 2024Review
- Article
- Article
- Sex Differences in Adiposity and Cardiovascular Diseases.International journal of molecular sciences · 2022Review
- The Role of Estrogens and Vitamin D in Cardiomyocyte Protection: A Female Perspective.Biomolecules · 2021Review
- Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.Endocrine · 2021Article
- The role of androgen and its related signals in PCOS.Journal of cellular and molecular medicine · 2021Review
- Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria.The Linacre quarterly · 2020Article
- Metabolic Perspectives for Non-classical Congenital Adrenal Hyperplasia With Relation to the Classical Form of the Disease.Frontiers in endocrinology · 2019Review
- Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.Vascular medicine (London, England) · 2017Article
- Higher prevalence of clinical cardiovascular comorbidities in postmenopausal women with self-reported premenopausal hirsutism and/or oligo-amenorrhea.Dermato-endocrinology · 2017Article
- Plasma total oxidant and antioxidant status after oral glucose tolerance and mixed meal tests in patients with polycystic ovary syndrome.Journal of endocrinological investigation · 2016Article
- Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study.Journal of endocrinological investigation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen excess (AE) was approximated to be present in 7% of the adult population of women. Polycystic ovary syndrome (PCOS) is the most prevalent among them, followed by idiopathic hirsutism (IH), congenital adrenal hyperplasia (CAH), hyperandrogenic insulin-resistant acanthosis nigricans (HAIRAN) syndrome, and androgen-secreting neoplasms (ASNs). Increased cardiovascular risk was implicated in women with AE. Serum testosterone independently increases risk for cardiovascular disease (CVD), and correlates even with indices of subclinical atherosclerosis in various populations of postmenopausal women. Hyperandrogenism in PCOS is closely related to the aggravation of abdominal obesity, and together with insulin resistance forming the metabolic core for the development of CVD. However, phenotypic variability of PCOS generates significant influence on the cardiometabolic risks. Numerous risk factors in PCOS lead to 5-7 times higher risk for CVD and over 2-fold higher risk for coronary heart disease and stroke. However, issue on the cardiometabolic risk in postmenopausal women with hyperandrogenic history is still challenging. There is a significant overlapping in the CVD characteristics of women with PCOS and variants of CAH. Relevant clinical data on the prevalence and cardiometabolic risk and events in women with IH, HAIRAN syndrome or ASNs are scarce. The effects of various oral contraceptives (OCs) and antiandrogenic compounds on metabolic profile are varying, and could be related to the selected populations and different therapy regiments mainly conducted in women with PCOS. It is assumed relation of OCs containing antiandrogenic progestins to the increased risk of cardiovascular and thromboembolic events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.